Investor Relations

Overview

PureTech is a biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases. We have created a broad and deep pipeline through the expertise of our experienced research and development team and our extensive network of scientists, clinicians and industry leaders.

For Investor Relations inquiries, please contact PureTech's Investor Relations team at: ir@puretechhealth.com.

View our corporate deck

Share Price

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Half Year Report 2022

 

Corporate Presentation 

 

Cash at Parent Level

$341.4M PureTech Level Cash and Cash Equivalents as of June 30, 2022 1 with an addition of up to ~$115.4M from the
sale of KRTX shares on August 8, 2022, post-period*

Analyst Coverage